References
- Patarroyo M. E., Romero E., Torres M. L., Clavijo P., Moreno A., Martinez R. R., Rodríguez R., Guzman F., Cabezas E. An induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 1987; 328: 629–632
- Valero M. V., Amador R., Galindo C., Figueroa J., Bello M. S., Murillo L. A., Nora A. L., Patarroyo G., Rocha C. L., Rojas M. Vaccination with SPf66, a chemically synthesized vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 1993; 341: 705–710, [CROSSREF]
- Valero M. V., Amador R., Aponte J. J., Narváez A., Galindo C., Silva Y., Rosas J., Guzman F., Patarroyo M. E. Evaluation of SPf66 malaria vaccine during a 22‐month follow‐up field trial in the Pacific coast of Colombia. Vaccine 1996; 14: 1466–1470, [CSA], [CROSSREF]
- Beck H. P., Felger I., Huber W., Steiger S., Smith T., Weiss N., Alonso P., Tanner M. Analysis of multiple Plasmodium falciparum infections in Tanzania children during the phase III trial of the malaria vaccine SPf66. J. Infect. Dis. 1997; 175: 921–926
- Graves P., Gelband H., Garner P. The SPf66 malaria vaccine: what is the evidence for efficacy?. Parasitol. Today 1998; 6: 218–220, [CROSSREF]
- International Conference of Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Validation of Analytical Procedures: Methodology (ICH‐Q2B). November, 1996. FDA Published, Federal Register, 1997; Vol. 62 (96): 27463–27467
- Santoveña A., Oliva A., Guzmán F., Patarroyo M., Llabrés M., Fariña J. B. Chromatographic characterization of synthetic peptides: SPf66 malaria vaccine. J. Chromatogr., B 2002; 766: 3–12, [CROSSREF]
- Oliva A., Dorta M. J., Santoveña A., Bonetto V., Salmona M., Fariña J. B. Characterization of antimalarial SPf66 peptide using MALDI‐TOF MS, CD and SEC. Peptides 2002; 23: 1527–1535, [CSA], [CROSSREF]
- Engers H. D., Godal T. Malaria vaccine development: current status. Parasitol. Today 1998; 14: 56–64, [CSA], [CROSSREF]
- Cleland J. L. Single‐administration vaccines: controlled‐release technology to mimic repeated immunizations. Trends Biotechnol. 1999; 17: 25–29, [CSA], [CROSSREF]
- Kersten G. F.A., Gander B. Biodegradable microspheres as vehicles for antigens. Concepts in Vaccine Development, S. H.E. Kaufmann. Walter de Gruyter, New York 1996; 265–302
- Conti S., Polonelli L., Frazzi R., Artusi M., Bettini R., Cocconi D., Colombo P. Controlled delivery of biotechnological products. Curr. Pharm. Biotechnol. 2000; 1: 313–323, [CSA]
- Sah H. Protein behaviour at the water/methylene chloride interface. J. Pharm. Sci. 1999; 88: 1320–1325, [CROSSREF]
- Fu K., Klibanov A. M., Langer R. Protein stability in controlled‐release systems. Nature 2000; 18: 24–25, [CROSSREF]
- Merrifield R. B. Solid‐phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 1963; 85: 2149–2154
- Houghten R. A. General method for the rapid solid‐phase synthesis of large numbers of peptides: specificity of antigen‐antibody interaction at the level of individual aminoacids. Proc. Natl. Acad. Sci. U.S.A. 1985; 82: 5131–5135
- Geigy J. R., Diem K. Tablas Científicas6th Ed. S.A.D.A.G., Spain 1965; 320–321